Acceptance and Commitment Therapy for Religious OCD

March 17, 2026 updated by: David Johnson, University of Alabama at Birmingham

Efficacy of Acceptance and Commitment Therapy on Religiously Oriented Obsessive-Compulsive Disorder

The purpose of the study is to examine the effects and feasibility of a specific form of psychotherapy, acceptance and commitment therapy (ACT), on religiously oriented obsessive and compulsive disorder (OCD).

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
10

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35233
        • Recruiting
        • University of Alabama at Birmingham
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • 18 years old
  • Meet cutoff scores for scrupulosity

Exclusion Criteria:

  • Presence of psychotic symptoms within six months of screening
  • Current suicidal/homicidal plan/intent and/or a suicide/homicide attempt within 6 months of screening
  • Non-suicidal self-injury within 6 months of screening
  • Narcotics use within 3 months of screening
  • Purging/restricting behavior within 3 months of screening.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Acceptance and Commitment Therapy
Participants will receive twelve consecutive weeks of acceptance and commitment therapy
Behavioral: Acceptance and Commitment Therapy
participants will then receive ACT-based individual therapy weekly for twelve weeks.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Scrupulosity Obsessions and Compulsions Scale
Time Frame: At baseline, 4 weeks, 8 weeks, and post-intervention (12 weeks)
The Scrupulosity Obsessions and Compulsions Scale (SOCS) is a 10-item scale that asks participants how often they experience religious OCD obsessions and compulsions. The questions are asked on a scale ranging from 0 (Very Rarely) to 5 (Very Often).
At baseline, 4 weeks, 8 weeks, and post-intervention (12 weeks)
Experiential Avoidance Rating Scale
Time Frame: At baseline, 4 weeks, 8 weeks, and post-intervention (12 weeks)
The Experiential Avoidance Rating Scale (EARS) is a 6-item scale that asks participants how true statements about avoiding experiences are for them. The questions are asked on a scale ranging from 1 (Never True) to 5 (Very Often True).
At baseline, 4 weeks, 8 weeks, and post-intervention (12 weeks)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Centrality of Religiosity Scale - Interreligious 20
Time Frame: Pre and post intervention which in general lasts 12 weeks
The Centrality of Religiosity Scale - Interreligious 20 (CRSi-20) is a 20-item scale assessing religiosity across 5 dimensions (Intellect, Ideology, Public practice, Private practice, Experience). The questions are asked on scales ranging from Never to Several times a day, Never to Very often, and Not at all to Very much so.
Pre and post intervention which in general lasts 12 weeks
Yale-Brown Obsessive and Compulsive Scale - Self Report
Time Frame: Pre and post intervention which in general lasts 12 weeks
The Yale-Brown Obsessive and Compulsive Scale (Y-BOCS) is a 12-item scale that asks participants whether they experience various OCD obsessions and compulsions. Participants are then asked how much time is spent on these obsessions and compulsions, whether they give in to the urge to perform compulsions, how strong the drive is to give in to compulsions, how they would feel if they were prevented from engaging in compulsions, and how much the compulsions and avoidance of compulsions interfere with their functioning.
Pre and post intervention which in general lasts 12 weeks
Patient Health Questionnaire - 9
Time Frame: Pre and post intervention which in general lasts 12 weeks
The Patient Health Questionnaire (PHQ-9) is a 9-item scale that asks participants how often they have been bothered by aspects of depressive symptoms. The questions are asked on a scale ranging from 0 (Not at all) to 5 (Nearly every day).
Pre and post intervention which in general lasts 12 weeks
Generalized Anxiety Disorder - 7
Time Frame: Pre and post intervention which in general lasts 12 weeks
The Generalized Anxiety Disorder Scale (GAD-7) is a 7-item scale that asks participants how often they have been bothered by statements capturing aspects of anxiety. The questions are asked on a scale ranging from 0 (Not at all) to 3 (Nearly every day).
Pre and post intervention which in general lasts 12 weeks
The Intrinsic Spirituality Scale
Time Frame: Pre and post intervention which in general lasts 12 weeks
The Intrinsic Spirituality Scale is a 6-item scale that asks participants about aspects of their spirituality.
Pre and post intervention which in general lasts 12 weeks
Psy-Flex
Time Frame: Pre and post intervention which in general lasts 12 weeks
The Psyflex questionnaire is a 6-item scale that measures aspects of psychological flexibility. The questions are asked on a scale ranging from very seldom to often.
Pre and post intervention which in general lasts 12 weeks
Almost Perfect Scale - Revised
Time Frame: Pre and post intervention which in general lasts 12 weeks
The Almost Perfect Scale - Revised is a 23-item scale that asks participants their agreement on items capturing perfectionism. The questions are asked on a scale ranging from 1 (Strongly disagree) to 7 (Strongly agree).
Pre and post intervention which in general lasts 12 weeks
The Alcohol Use Disorders Identification Test
Time Frame: Pre and post intervention which in general lasts 12 weeks
The Alcohol Use Disorders Identification Test (AUDIT) is a 10-item scale that asks participants about their alcohol consumption.
Pre and post intervention which in general lasts 12 weeks
National Institute on Drug Abuse Screener
Time Frame: Pre and post intervention which in general lasts 12 weeks
National Institute on Drug Abuse Screener (NIDA) is a 1-item scale that asks participants how often they use a variety of substances. The questions are asked on a scale ranging from Never to Daily or Almost Daily.
Pre and post intervention which in general lasts 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Alabama at Birmingham

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 30, 2025

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
September 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
September 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
October 16, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 16, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
October 18, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 19, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 17, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 300013565-001
  • UAB (Other Identifier: UAB)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obsessive-Compulsive Disorder (OCD)

Clinical Trials on Acceptance and Commitment Therapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings